A Comprehensive Review of Diabetes: Clinical Features, Causes, Treatment Strategies, and Early Detection

Abstract

Diabetes Mellitus (DM) is a chronic metabolic disorder that results in elevated blood glucose levels due to either insufficient insulin production or the body’s inability to utilize insulin effectively. It affects millions worldwide and can lead to significant morbidity and mortality if not managed properly. This review provides an in-depth examination of the pathophysiology, diagnosis, and treatment strategies of diabetes mellitus. The paper outlines the various types of diabetes, focusing on type 1 and type 2 diabetes, including their etiologies, clinical manifestations, diagnostic approaches, and the latest treatment modalities. The role of lifestyle modifications, pharmacological interventions, and emerging therapies such as artificial pancreas and gene therapy are discussed. This review aims to enhance the understanding of diabetes mellitus and provide comprehensive insights into its management, which is critical in reducing the global burden of this disease.

Keywords

Introduction

Diabetes Mellitus (DM) is a chronic, progressive metabolic disorder that arises when the body is unable to produce sufficient insulin, or when the insulin produced is ineffective in regulating blood glucose levels. Insulin, a hormone secreted by the β-cells of the pancreas, plays a central role in maintaining glucose homeostasis. A disruption in its production or function leads to persistent hyperglycemia, the hallmark of diabetes. DM encompasses a spectrum of disorders primarily classified into Type 1 Diabetes Mellitus (T1D) and Type 2 Diabetes Mellitus (T2D). T1D is an autoimmune disorder characterized by the destruction of insulin-producing pancreatic β-cells, while T2D results from a combination of insulin resistance and a relative deficiency in insulin secretion.^[1] As per the International Diabetes Federation (IDF), the global burden of diabetes affected approximately 463 million adults in 2019, and this number is projected to reach 700 million by 2045.^[2] The disease contributes significantly to morbidity and mortality due to its association with severe complications such as cardiovascular diseases, nephropathy, neuropathy, and diabetic retinopathy.^[3] In addition to these microvascular and macrovascular complications, diabetes imposes a considerable economic burden on individuals and healthcare systems worldwide.^[4]

Figure 1: Illustration of Normal and Hyperglycemic Blood Glucose Levels ^[1]

Risk factors for T2D include genetic predisposition, obesity, sedentary lifestyle, poor dietary habits, and increasing age, while T1D is predominantly influenced by genetic and environmental factors triggering autoimmune destruction.^[5] The pathophysiology of DM involves complex interactions between genetic, epigenetic, and environmental influences that affect pancreatic β-cell function and insulin signaling pathways.^[6] Diagnosis of diabetes is typically based on plasma glucose criteria, including fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), and glycated hemoglobin (HbA1c) levels.^[7] Management strategies for DM emphasize glycemic control through lifestyle interventions diet modification, physical activity and pharmacological treatments such as oral hypoglycemic agents, non-insulin injectables, and insulin therapy.^[8] Emerging therapeutic approaches include incretin-based therapies (e.g., GLP-1 receptor agonists), SGLT2 inhibitors, and novel insulin analogs. Furthermore, preventive strategies like community-based awareness programs, early screening for high-risk groups, and personalized medicine are gaining attention in combating the diabetes epidemic.^[9] This review will further explore the etiology, pathophysiology, diagnosis, and current as well as emerging management strategies of Diabetes Mellitus, with an emphasis on translational research and preventive frameworks.

Pathophysiology of Diabetes Mellitus: The pathophysiology of diabetes mellitus is complex and varies depending on the type of diabetes. In T1D, the autoimmune destruction of pancreatic β-cells leads to an absolute insulin deficiency. In contrast, T2D is primarily associated with insulin resistance, where the body’s cells fail to respond adequately to insulin, coupled with a relative impairment in insulin secretion. Over time, this results in elevated blood glucose levels. The pathophysiology differs between Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM).

Type 1 Diabetes (T1D)

Type 1 Diabetes (T1D) is a complex autoimmune disease characterized by the progressive destruction of insulin-producing β-cells in the pancreas, leading to an absolute insulin deficiency. The pathogenesis of T1D involves both genetic and environmental factors that act in concert to initiate the disease. Genetic predisposition plays a crucial role, with specific alleles of the HLA (Human Leukocyte Antigen) system, particularly HLA-DR3 and HLA-DR4, being strongly associated with an increased risk of developing T1D. These genetic variants affect immune system functioning, particularly in the activation of autoreactive T cells, which are central to the autoimmune process. However, genetics alone are insufficient to trigger the disease, indicating that environmental factors are also essential.^[10]

Environmental factors, especially viral infections, are believed to be the primary triggers for T1D onset. Viruses such as enteroviruses, rotaviruses, and rubella have been implicated in the initiation of the autoimmune response. These infections can lead to molecular mimicry, where viral antigens resemble self-antigens on β-cells, prompting an immune attack.^[11] Additionally, other environmental triggers, including early exposure to cow’s milk proteins, vitamin D deficiency, or changes in the gut microbiome, have been proposed to influence susceptibility, though the exact mechanisms remain unclear.^[12]

As the immune system becomes activated, autoantibodies begin to form, and they target key β-cell antigens. Among these, insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD65), insulinoma- associated antigen-2 (IA-2), and zinc transporter 8 (ZnT8) are the most commonly detected in individuals at risk for T1D. The presence of these autoantibodies can be detected years before the onset of clinical symptoms and serve as important biomarkers for early diagnosis.^[13] The appearance of multiple autoantibodies is associated with an increased risk of disease progression. These autoantibodies bind to their respective antigens on the surface of β-cells and are believed to trigger an inflammatory immune response. The immune attack itself is primarily mediated by autoreactive T cells, which infiltrate the pancreatic islets, a process known as insulitis. These T cells, which are typically involved in defending against infections, mistakenly recognize β-cells as foreign and initiate their destruction through various mechanisms, including the release of pro-inflammatory cytokines (e.g., interferon-γ and tumor necrosis factor-α) and direct cytotoxicity.^[14]

The loss of β-cell function in T1D results in a gradual but eventual absolute insulin deficiency. Insulin is crucial for regulating blood glucose levels by promoting glucose uptake into cells for energy production and storage. Without sufficient insulin, glucose accumulates in the bloodstream, leading to hyperglycemia, which is the hallmark of T1D. As the disease progresses, the patient’s pancreas can no longer compensate for the lack of insulin, and individuals become dependent on exogenous insulin administration. This insulin therapy is required for life to prevent life-threatening complications such as diabetic ketoacidosis (DKA) and to control blood glucose levels to reduce the risk of long-term complications like neuropathy, nephropathy, and retinopathy.^[15]

Type 2 Diabetes (T2D)

In Type 2 Diabetes Mellitus (T2DM), the pathogenesis is multifactorial, involving a complex interplay between genetic predisposition and   obesity, and unhealthy dietary habits.^[16] Central to its development are insulin resistance and progressive β-cell dysfunction. In the early stages, insulin resistance primarily affects skeletal muscle, adipose tissue, and the liver, impairing glucose uptake and increasing hepatic gluconeogenesis.^[17] To compensate, pancreatic β-cells augment insulin secretion, often resulting in hyperinsulinemia. However, chronic overstimulation eventually leads to β-cell exhaustion, apoptosis, and relative insulin deficiency.^[18] Lipotoxicity and glucotoxicity are critical contributors to β-cell dysfunction. Excessive free fatty acids and chronic hyperglycemia induce oxidative stress, endoplasmic reticulum stress, and inflammatory responses that impair β-cell survival.^[19] Simultaneously, adipose tissue, especially visceral fat, releases adipokines (like resistin and leptin) and pro-inflammatory cytokines (e.g., TNF-α, IL-6) that interfere with insulin signaling pathways.^[20]  Genetically, polymorphisms in genes such as TCF7L2, PPARG, and KCNJ11 have been implicated in increasing the risk of T2DM by modulating insulin secretion and action.^[21] Long-term uncontrolled T2DM can result in both microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular complications (cardiovascular disease and stroke).^[22]

In contrast, Gestational Diabetes Mellitus (GDM) is a condition of glucose intolerance with onset or first recognition during pregnancy, usually diagnosed in the second or third trimester. It results primarily from the insulin-antagonistic effects of placental hormones, such as human placental lactogen (hPL), progesterone, and cortisol, which lead to physiological insulin resistance in pregnancy.^[23] In women with underlying β-cell dysfunction or genetic predisposition, this adaptive insulin resistance surpasses the compensatory insulin response, resulting in hyperglycemia.^[24]

Figure 1: Mechanisms of Glucose Regulation in Healthy Individuals vs Type 1 and Type 2 Diabetes

In advanced stages, patients may develop diabetic complications, which can include diabetic retinopathy, nephropathy, neuropathy, and an increased risk of cardiovascular disease.^[32]

Diagnostic Criteria

The diagnosis of diabetes mellitus is based on standardized biochemical criteria established primarily by the American Diabetes Association (ADA), the World Health Organization (WHO), and other expert bodies. Accurate diagnosis is essential for initiating appropriate treatment and preventing complications. Four major diagnostic parameters are widely accepted:

1. Fasting Plasma Glucose (FPG): A plasma glucose level ≥ 126 mg/dL (7.0 mmol/L) after an overnight fast of at least 8 hours is diagnostic. Fasting glucose is a convenient and low-cost method but may miss cases of postprandial hyperglycemia.^[35]
2. 2-Hour Plasma Glucose during an Oral Glucose Tolerance Test (OGTT): A level ≥ 200 mg/dL (11.1 mmol/L) two hours after ingestion of a 75g oral glucose load indicates diabetes. This test evaluates postprandial glucose handling and can identify impaired glucose tolerance (IGT), which is an intermediate state of hyperglycemia.^[36]
3. Hemoglobin A1c (HbA1c): A value ≥ 6.5% is considered diagnostic. HbA1c reflects average plasma glucose over the past 2–3 months, providing a picture of chronic glycemic exposure. It has gained popularity because it does not require fasting and is less affected by acute stress or illness.^[37] However, its limitations include interference from hemoglobinopathies, anemia, iron deficiency, and recent transfusions.^[38]
4. Random Plasma Glucose: A level ≥ 200 mg/dL (11.1 mmol/L) in the presence of classical symptoms of hyperglycemia such as polyuria, polydipsia, and unexplained weight loss is diagnostic.^[39] This criterion is particularly useful in emergency or acute care settings.

While any of the above tests may be used for diagnosis, results should be confirmed with repeat testing on a different day unless there is unequivocal hyperglycemia with acute metabolic decompensation.^[40]

Screening is recommended for asymptomatic individuals at high risk for diabetes. These include persons with a BMI ≥ 25 kg/m² (≥ 23 kg/m² in Asian Americans), first-degree relatives with diabetes, history of gestational diabetes mellitus (GDM), hypertension, dyslipidemia, or women with polycystic ovary syndrome (PCOS). The ADA recommends initiating screening at age 35 in all adults and repeating testing every three years if results are normal.^[41]

Newer modalities, including continuous glucose monitoring (CGM), though not yet used for diagnosis, are proving valuable in early identification of glycemic abnormalities, especially in high-risk or prediabetic individuals.^[42]

Further considerations include:

1. OGTT remains the gold standard for detecting postprandial hyperglycemia.
2. HbA1c, while convenient, may yield falsely low or high results due to factors affecting red cell turnover.
3. Ethnic differences in glycation rates may influence HbA1c interpretations.
4. In resource-limited settings, fasting glucose testing remains the most accessible diagnostic approach.^[43]

Management and Treatment Strategies:

Effective management of diabetes mellitus requires a comprehensive, individualized approach that integrates lifestyle modifications, pharmacologic therapy, regular monitoring, and the prevention of acute and chronic complications.^[44] Lifestyle Modification remains the cornerstone of diabetes management. Medical Nutrition Therapy (MNT) focuses on achieving optimal glycemic control, weight management, and cardiovascular risk reduction. A Mediterranean-style diet rich in monounsaturated fats, fiber, and whole grains, or a low-glycemic index diet, has demonstrated benefits in glycemic control and insulin sensitivity.^[45] Patients are encouraged to avoid processed sugars and saturated fats, while emphasizing nutrient-dense food choices. Physical activity improves insulin action and glycemic control. The ADA and WHO recommend at least 150 minutes per week of moderate-intensity aerobic exercise (e.g., brisk walking, cycling) distributed over at least 3 days per week with no more than 2 consecutive days without activity.^[46] Resistance training at least twice per week is also beneficial. Glycemic Monitoring is essential for assessing the effectiveness of therapy. Self-Monitoring of Blood Glucose (SMBG) is advised for patients on insulin or sulfonylureas. Continuous Glucose Monitoring (CGM) provides real-time feedback, detects glycemic variability, and has been shown to improve HbA1c levels in both type 1 and insulin-treated type 2 diabetes.^[47] Metrics such as “Time in Range (TIR)” are now recognized as valuable indicators of control. Pharmacotherapy must be tailored to individual needs, comorbidities, and risk profiles. For Type 1 diabetes, insulin therapy is essential. In Type 2 diabetes, metformin is the first-line agent unless contraindicated. Other classes include:

1. SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin), which improve cardiovascular and renal outcomes.
2. GLP-1 receptor agonists (e.g., liraglutide, semaglutide), which promote weight loss and reduce atherosclerotic cardiovascular disease risk.
3. DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and insulin therapy as needed based on glycemic goals and patient characteristics.^[48]

Individualized Glycemic Targets: While a general HbA1c goal of <7% is recommended, less stringent targets may be appropriate for older adults or those with multiple comorbidities, while more stringent control (<6.5%) may be pursued in younger, healthier patients without hypoglycemia risk.^[49]

Prevention of Complications involves annual screening for:

1. Diabetic Retinopathy: Fundus examination.
2. Nephropathy: Urine albumin-to-creatinine ratio.
3. Neuropathy: Foot examinations and monofilament testing.

Aggressive control of comorbidities including hypertension, dyslipidemia, and smoking cessation is vital. ACE inhibitors or ARBs are preferred for hypertension in diabetic patients, and statins are recommended for most adults over 40 with diabetes, regardless of baseline LDL levels.^[50] Psychosocial support, patient education, and behavioral counseling play crucial roles in adherence and long-term success. Diabetes distress, depression, and anxiety should be routinely evaluated, especially in youth and those with poorly controlled disease?¹.

Pharmacological Therapy

Pharmacological therapy for diabetes mellitus is individualized based on the type of diabetes, comorbid conditions, glycemic status, patient preferences, and risk factors such as hypoglycemia or cardiovascular disease. For Type 2 Diabetes Mellitus (T2D), oral agents are typically initiated, whereas Type 1 Diabetes Mellitus (T1D) requires insulin from the outset.^[51]

1. Oral Hypoglycemic Agents:

Metformin is the first-line agent for most patients with T2D. It lowers blood glucose primarily by reducing hepatic gluconeogenesis and enhancing insulin sensitivity in peripheral tissues. It is weight-neutral and has a favorable safety profile, with rare risk of lactic acidosis. Metformin also shows potential cardiovascular benefits and cancer risk reduction in observational studies.^[52]

Sulfonylureas (e.g., glipizide, glyburide) increase insulin secretion by stimulating pancreatic β-cells. Though effective in the short term, they are associated with weight gain and hypoglycemia. Their use has declined with the emergence of safer alternatives.^[53]

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (e.g., sitagliptin, linagliptin) enhance incretin activity, increasing insulin release and suppressing glucagon secretion in a glucose-dependent manner. These agents are weight-neutral and well-tolerated but provide modest HbA1c reductions.^[54]

Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) (e.g., empagliflozin, dapagliflozin) promote glycosuria by inhibiting renal glucose reabsorption. They not only lower glucose but also reduce the risk of heart failure and progression of chronic kidney disease, making them valuable in patients with cardiovascular or renal disease.^[55]

Glucagons-Like Peptide-1 Receptor Agonists (GLP-1 RAs) (e.g., liraglutide, semaglutide) enhance insulin secretion, inhibit glucagon, delay gastric emptying, and promote satiety. They are effective for weight loss and have demonstrated cardiovascular benefits, particularly in patients with established atherosclerotic cardiovascular disease.^[56]

2. Insulin Therapy:

Insulin remains essential for all patients with T1D and is required in many with T2D who have significant β-cell dysfunction. Therapy includes:

1. Basal Insulins (e.g., glargine, detemir) to manage fasting glucose.
2. Prandial (Bolus) Insulins (e.g., aspart, lispro) to control postprandial spikes.
3. Premixed Insulins offer simplified regimens for select patients.^[57]

3. Emerging and Combination Therapies:

Dual GIP/GLP-1 agonists such as tirzepatide, which provide robust HbA1c reduction and significant weight loss showing superiority over GLP-1 RAs in some trials.^[58] Fixed-ratio combination therapies (e.g., basal insulin + GLP-1 RA) enhance efficacy and simplify treatment while minimizing weight gain and hypoglycemia risk.^[59]

Diabetic Complications:  The long-term complications of diabetes mellitus arise primarily from chronic hyperglycemia, which induces damage through mechanisms such as non-enzymatic glycation of proteins, increased oxidative stress, and inflammatory responses. These complications can be broadly categorized into macrovascular and microvascular disorders.

1. Cardiovascular Disease (CVD): People with diabetes have a significantly increased risk of atherosclerotic cardiovascular disease, including coronary artery disease, stroke, and peripheral arterial disease. Chronic hyperglycemia contributes to endothelial dysfunction, increased platelet aggregation, and lipid abnormalities, all of which promote atherogenesis. Diabetic patients are 2-4 times more likely to develop cardiovascular events compared to non-diabetics.^[60]
2. Diabetic Retinopathy: This is a leading cause of blindness among working-age adults globally. Hyperglycemia-induced damage to retinal capillaries leads to microaneurysms, retinal hemorrhages, and eventually neovascularization in proliferative diabetic retinopathy. Risk factors include disease duration, poor glycemic control, and hypertension.^[61]
3. Diabetic Nephropathy: Characterized by albuminuria, hypertension, and decline in glomerular filtration rate, diabetic nephropathy is the leading cause of end-stage renal disease (ESRD) worldwide. Persistent hyperglycemia promotes glomerular basement membrane thickening, mesangial expansion, and glomerulosclerosis.^[62]
4. Diabetic Neuropathy: Diabetic neuropathy affects nearly 50% of patients with long-standing diabetes. Peripheral neuropathy causes tingling, burning pain, numbness, and increases the risk of foot ulcers and amputations. Autonomic neuropathy can result in gastroparesis, erectile dysfunction, orthostatic hypotension, and bladder dysfunction.^[63]

Other Complications:         

1. Diabetic foot ulcers: Result from a combination of neuropathy, ischemia, and infection.
2. Increased susceptibility to infections: Due to impaired immune response, especially neutrophil function.
3. Cognitive impairment and dementia: Emerging evidence suggests an association between diabetes and Alzheimer’s disease.^[64]

Preventive Strategies:

Primary prevention aims to prevent the onset of diabetes in individuals at risk. It emphasizes:

Healthy diet: A diet rich in whole grains, fruits, vegetables, lean proteins, and healthy fats can significantly reduce diabetes risk. High consumption of processed foods and sugar-sweetened beverages is associated with an increased incidence of T2D.^[65]

Physical activity: Regular moderate-intensity physical activity (at least 150 minutes per week) improves insulin sensitivity and helps maintain healthy body weight.^[66]

Weight management: Obesity, particularly central adiposity, is a major modifiable risk factor. Even modest weight loss (5-10% of body weight) has been shown to substantially reduce diabetes risk.^[67]

Behavioral modification: Lifestyle education and behavioral counseling have demonstrated long-term effectiveness in diabetes prevention.

Notably, the Diabetes Prevention Program (DPP) in the United States showed that lifestyle interventions reduced the incidence of T2D by 58%, compared to 31% with metformin.^[68]

Secondary prevention focuses on early detection and intervention in high-risk groups, such as individuals with prediabetes, obesity, hypertension, or a family history of diabetes. Screening programs using fasting plasma glucose, HbA1c, or oral glucose tolerance tests (OGTT) can help identify at-risk individuals.  Pharmacologic interventions, such as metformin, may be considered in high-risk individuals who are unable to achieve adequate lifestyle changes.^[69] Early intervention at this stage can delay or prevent the progression from prediabetes to full blown diabetes.

Tertiary prevention is aimed at individuals already diagnosed with diabetes and involves:

1. Glycemic control through medications, insulin therapy, and lifestyle management.
2. Monitoring and treating comorbidities such as hypertension, dyslipidemia, and obesity.
3. Routine screening for complications such as nephropathy, retinopathy, and neuropathy.
4. Patient education to enhance self-care, foot care, and medication adherence.

These strategies help prevent or delay the progression of complications, improving quality of life and reducing healthcare costs.^[70]

CONCLUSION

Diabetes Mellitus remains a major global health challenge with significant impacts on individuals, healthcare systems, and economies. With the growing prevalence of the disease, especially T2D, there is an urgent need for effective prevention, early detection, and management strategies. Advancements in pharmacological treatments, along with a better understanding of the disease’s pathophysiology, offer hope for improved outcomes. Lifestyle changes remain the cornerstone of diabetes management, but innovative therapies continue to improve patient care. A multi-disciplinary approach involving healthcare providers, policymakers, and individuals is crucial to managing the diabetes epidemic and its associated complications.

ACKNOWLEDGEMENTS:

We would like to thank the researchers and healthcare professionals whose work contributed to the development of this review. We also acknowledge the support of our institutions and the funding agencies.

REFERENCES

1. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2014; 37(Suppl 1): S81–S90.
2. Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th edition. Brussels: International Diabetes Federation; 2021. Available from: 
3. Fowler MJ. Microvascular and macrovascular complications of diabetes. Clin Diabetes 2008; 26(2): 77–82. 
4. Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: A global systematic review. PharmacoEconomics 2015; 33(8): 811–831. 
5. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865): 782–787. 
6. Ashcroft FM, Rorsman P. Diabetes mellitus and the β cell: the last ten years. Cell 2012; 148(6): 1160–1171. 
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15(7): 539–553. 
8. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for initiation and adjustment of therapy. Diabetes Care 2009; 32(1): 193–203. 
9. Reddy TK, Villavaso CD, Pulapaka AV, Ferdinand KC. Achieving equitable access to incretin-based therapies in cardiovascular care. Am Heart J Plus 2024; 46: 100455. 
10. Lucier J, Mathias PM. Type 1 Diabetes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2024 Oct 5. Available from: 
11. Alves Abrantes JJP, Veríssimo de Azevedo JC, Fernandes FL, et al. Viruses as a potential environmental trigger of type 1 diabetes mellitus (Review). Biomed Rep 2024; 20(5): 81. 
12. Moriki D, Francino MP, Koumpagioti D, et al. The role of the gut microbiome in cow's milk allergy: a clinical approach. Nutrients 2022; 14(21): 4537. 
13. Niechcia? E, Rogowicz-Frontczak A, Pi?aci?ski S, et al. Autoantibodies against zinc transporter 8 are related to age and metabolic state in patients with newly diagnosed autoimmune diabetes. Acta Diabetol 2018; 55(3): 287–294. 
14. McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008; 98: 121–149.
15. Sims EK, Mirmira RG, Evans-Molina C. The role of beta-cell dysfunction in early type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2020; 27(4): 215–224. 
16. Galicia-Garcia U, Benito-Vicente A, Jebari S, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci 2020; 21(17): 6275. 
17. Wilcox G. Insulin and insulin resistance. Clin Biochem Rev 2005; 26(2): 19–39.
18. Nichols CG, Remedi MS. The diabetic β-cell: hyperstimulated vs. hyperexcited. Diabetes Obes Metab 2012; 14 Suppl 3: 129–135. 
19. Cerf ME. Beta cell dysfunction and insulin resistance. Front Endocrinol 2013; 4: 37. 
20. Balistreri CR, Caruso C, Candore G. The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm 2010; 2010: 802078. 
21. Haghvirdizadeh P, Mohamed Z, Abdullah NA, et al. KCNJ11: Genetic polymorphisms and risk of diabetes mellitus. J Diabetes Res 2015; 2015: 908152. 
22. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008; 88(11): 1322–1335. 
23. Kunarathnam V, Vadakekut ES, Mahdy H. Gestational Diabetes. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2025 Sep 15. Available from: 
24. Usman TO, Chhetri G, Yeh H, Dong HH. Beta-cell compensation and gestational diabetes. J Biol Chem. 2023;299(12):105405.  
25. Kumar J, Rehman T, Barkat R, et al. A comparative analysis of clinical features of diabetes mellitus type 2 with respect to duration of diabetes. Cureus 2024; 16(11): e74849.
26. Dhatariya K, Mustafa O, Stathi D. Hyperglycemic Crises. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Updated 2025 Jun 10. Available from: 
27. Mottalib A, Kasetty M, Mar JY, et al. Weight management in patients with type 1 diabetes and obesity. Curr Diabetes Rep 2017; 17(10): 92. 
28. Spampinato SF, Caruso GI, De Pasquale R, et al. The treatment of impaired wound healing in diabetes: looking among old drugs. Pharmaceuticals 2020; 13(4): 60. 
29. Kropp M, Golubnitschaja O, Mazurakova A, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications risks and mitigation. EPMA J 2023; 14(1): 21–42.
30. Rout P, Jialal I. Diabetic nephropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2025 Jan 9. Available from: 
31. Bodman MA, Dreyer MA, Varacallo MA. Diabetic peripheral neuropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2024 Feb 25. Available from: 
32. De Rosa S, Arcidiacono B, Chiefari E, Brunetti A, Indolfi C, Foti DP. Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links. Front Endocrinol 2018; 9: 2. 
33. Parveen K, Hussain MA, Anwar S, et al. Comprehensive review on diabetic foot ulcers and neuropathy: treatment, prevention and management. World J Diabetes 2025; 16(3): 100329. 
34. Carmichael J, Fadavi H, Ishibashi F, et al. Advances in screening, early diagnosis and accurate staging of diabetic neuropathy. Front Endocrinol 2021; 12: 671257. 
35. Nelson M, Dungan KM. Diagnostic tests for diabetes mellitus. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Updated 2025 Feb 7. 
36. Zubair M, Launico MV. Glucose tolerance test. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2025 Sep 15. Available from: 
37. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights 2016; 11: 95–104. 
38. Zhu NA, Reichert S, Harris SB. Limitations of hemoglobin A?c in the management of type 2 diabetes mellitus. Can Fam Physician 2020; 66(2): 112–114.
39. ElSayed NA, Aleppo G, Aroda VR, et al.; on behalf of the American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes-2023. Diabetes Care 2023; 46(Suppl 1): S19–S40. 
40. Sacks DB, Arnold M, Bakris GL, et al.; National Academy of Clinical Biochemistry; Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34(6): e61-e99. 
41. Araneta MR, Kanaya AM, Hsu WC, et al. Optimum BMI cut points to screen Asian Americans for type 2 diabetes. Diabetes Care 2015; 38(5): 814–820.  2071
42. Soliman A, DeSanctis V, Yassin M, Elalaily R, Eldarsy NE. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab 2014; 18(3): 274–282.
43. López López R, Fuentes García R, González-Villalpando ME, González-Villalpando C. Diabetic by HbA1c, normal by OGTT: a frequent finding in the Mexico City Diabetes Study. J Endocr Soc 2017; 1(10): 1247–1258. 
44. Sugandh F, Chandio M, Raveena F, et al. Advances in the management of diabetes mellitus: a focus on personalized medicine. Cureus 2023; 15(8): e43697. 
45. Gerontiti E, Shalit A, Stefanaki K, et al. The role of low glycemic index and load diets in medical nutrition therapy for type 2 diabetes: an update. Hormones (Athens) 2024; 23(4): 655–665.
46. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care 2016; 39(11): 2065-2079.
47. Zou Y, Zhao S, Li G, Zhang C. The efficacy and frequency of self-monitoring of blood glucose in non-insulin-treated T2D patients: a systematic review and meta-analysis. J Gen Intern Med 2023; 38(3): 755–764. 
48. Ghosh K, Chandra S, Ghosh S, Ghosh US. Artificial intelligence in personalized medicine for diabetes mellitus: a narrative review. Cureus 2025; 17(9): e91520. 
49. Lee SJ, Eng C. Goals of glycemic control in frail older patients with diabetes. JAMA 2011; 305(13): 1350–1351.
50. Naha S, Gardner MJ, Khangura D, et al. Hypertension in diabetes. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Updated 2021 Aug 7. Available from: 
51. Kalra S, Jena BN, Yeravdekar R. Emotional and psychological needs of people with diabetes. Indian J Endocrinol Metab 2018; 22(5): 696–704. 
52. Corcoran C, Jacobs TF. Metformin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2023 Aug 17. Available from: 
53. Sola D, Rossi L, Schianca GP, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci 2015; 11(4): 840–848. 
54. Kasina SVSK, Baradhi KM. Dipeptidyl peptidase IV (DPP IV) inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2023 May 22. Available from: 
55. Padda IS, Mahtani AU, Parmar M. Sodium-glucose transport 2 (SGLT2) inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2025 Sep 15. Available from:
56. Collins L, Costello RA. Glucagon-like peptide-1 receptor agonists. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2024 Feb 29. Available from: 
57. Jarosinski MA, Chen YS, Varas N, et al. New horizons: next-generation insulin analogues: structural principles and clinical goals. J Clin Endocrinol Metab 2022; 107(4): 909–928. 
58. Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. Cardiovasc Diabetol 2022; 21(1): 169. 
59. Kurkin DV, Bakulin DA, Morkovin EI, et al. Problemy endokrinologii 2024; 70(1): 91-99. 
60. Siam NH, Snigdha NN, Tabasumma N, Parvin I. Diabetes mellitus and cardiovascular disease: exploring epidemiology, pathophysiology, and treatment strategies. Rev Cardiovasc Med 2024; 25(12): 436.
61. Shukla UV, Tripathy K. Diabetic retinopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2023 Aug 25. Available from: 
62. Samsu N. Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. BioMed Research International. 2021;2021:1497449.  
63. Hammi C, Yeung B. Neuropathy. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Updated 2022 Oct 15. Available from:   
64. Brognara L, Volta I, Cassano VM, Navarro-Flores E, Cauli O. The association between cognitive impairment and diabetic foot care: role of neuropathy and glycated hemoglobin. Pathophysiology 2020; 27(1): 14–27. 
65. Reynolds A, Mitri J. Dietary advice for individuals with diabetes. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Updated 2024 Apr 28. Available from: 
66. Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med 2017; 84(7 Suppl 1): S15–S21. 
67. Franz MJ. Weight management: obesity to diabetes. Diabetes Spectr 2017; 30(3): 149–153. 
68. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002; 25(12): 2165–2171. 
69. Duan D, Kengne AP, Echouffo-Tcheugui JB. Screening for diabetes and prediabetes. Endocrinol Metab Clin North Am 2021; 50(3): 369–385. 
70. Psaltopoulou T, Ilias I, Alevizaki M. The role of diet and lifestyle in primary, secondary, and tertiary diabetes prevention: a review of meta-analyses. Rev Diabet Stud 2010; 7(1): 26–35.